The emergence of somatostatin antagonist-based theranostics: Paving the road toward another success?

Alessio Imperiale; Abhishek Jha; Leah Meuter; Guillaume P Nicolas; David Taïeb; Karel Pacak

doi:10.2967/jnumed.123.265406

The emergence of somatostatin antagonist-based theranostics: Paving the road toward another success?

J Nucl Med. 2023 Feb 9;jnumed.123.265406. doi: 10.2967/jnumed.123.265406. Online ahead of print.

Authors

Alessio Imperiale¹, Abhishek Jha², Leah Meuter², Guillaume P Nicolas³, David Taïeb⁴, Karel Pacak²

Affiliations

¹ Nuclear Medicine and Molecular Imaging, ICANS, Strasbourg University, France.
² Eunice Kennedy Shriver NICHD, National Institutes of Health, United States.
³ Div. of Nuclear Medicine, Center for Neuroendocrine and Endocrine Tumors, University Hospital Basel, Switzerland.
⁴ La Timone University Hospital, CERIMED, Aix-Marseille University.

PMID: 36759198
DOI: 10.2967/jnumed.123.265406

No abstract available

Keywords: Gastrointestinal; Molecular Imaging; Neuroendocrine; Oncology: GI; PET/CT; Peptides; Radionuclide Therapy; Radiopharmaceuticals; Somatostatin; agonist; antagonist; neuroendocrine tumors; theranostics.